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ABSTRACT
We conducted a systematic review of genetic association
studies for osteoarthritis of the peripheral joints (OA) and
spinal degenerative disease (SDD). Electronic searches
were carried out for any English language article reporting
on a gene association study for either OA or SDD
published up until the end of 2006. A team of seven
reviewers used a standardised template to extract data in
duplicate. In all, 90 studies fulfilled our inclusion criteria,
reporting a total of 94 significant associations from 83
different genes. We found relatively few instances in
which a specific gene–disease association had been
analysed by more than one study, and there were 14
cases in which significant associations were replicated in
independent studies (at joints associated with the AGC1,
ASPN, COL9A2, COL9A3, COL11A2, ESR1, FZRB, HFE,
IL1A, IL1RN, PTGS2 and VDR genes). Methodological and
reporting problems were widespread, including failure to
report full results, missing population details, multiple
testing, and over-reliance on subgroup analysis. In
summary, the complex phenotypes of OA and SDD may
have made it difficult for researchers to focus their efforts.
The field is dominated by isolated analyses of disparate
potential associations, a problem that is amplified by the
frequent analysis of different polymorphisms within
individual genes. Flaws in study methodology and
interpretation undoubtedly increase the risk of publication
bias. Closer adherence to published recommendations (in
particular those produced by HuGENet) will help to ensure
that future studies are well-designed and build on current
understanding, rather than simply adding to the growing
bank of potential associations.
Twin and family studies demonstrate that
between a half and two-thirds of the occurrences
of osteoarthritis (OA) can be attributed to genetic
factors.1 This finding has justifiably stimulated the
search for specific genes,2–5 but the task is formid-
able, as has proven to be the case for other types of
complex disease. Genetic factors may vary with the
pattern and severity of disease and according to
patient characteristics, such as gender and age. OA
can also have a range of clinical and radiographic
definitions, which further increases the difficulty.
For example, while peripheral joint OA and spinal
degenerative disease (SDD) share pathological and
clinical features, the extent to which the aetiolo-
gical determinants of these disease processes are
similar is not known.
Genetic association studies provide a means of
quantifying the effects of specific gene variants on
disease occurrence, but interpreting such data can
be problematic. Sample sizes, sample selection,
population stratification effects, and differences in
the pattern of confounding may all have an
impact.6 Over the last two decades a large number
of gene–OA association studies have been con-
ducted, and it is increasingly recognised that an
objective appraisal of such studies can only be
approached through systematic review. To date
the consistency of the results of all published
studies of OA and SDD have not been evaluated in
this way.
In this review, therefore, we aimed to retrieve
and review all gene–OA and gene–SDD association
studies that have been published to date in peer-
reviewed, English language journals. Our first
objective was to carry out a broad ranging
systematic review of genetic association studies.
We aimed to document the number of genes that
have been screened and to assess the degree to
which analyses of individual genes have been
replicated by more than one study. Our second
objective was to describe common methodological
and reporting problems encountered within gene–
OA/SDD association studies and to assess the
frequency with which these problems occurred.
Thus, we aim to help improve the way in which
future studies are conducted in this rapidly
expanding field.
LITERATURE REVIEW METHODOLOGY
Inclusion and exclusion criteria
A deliberately broad search strategy was used in
which gene–OA and gene–SDD association studies
of any design, dealing with any gene, were judged
suitable for inclusion. We aimed to review associa-
tions on a per gene basis: included studies could
therefore test for association with regard to one or
more genetic polymorphism(s) within a particular
gene. We excluded conference abstracts, review
papers and non-English language papers.
Search strategy
Electronic searches were performed on Medline and
Embase (using the Ovid platform, beginning with
1966 for Medline, and 1980 for Embase) and on the
Science Citation Index (SCI; Thompson Web of
Knowledge), for all studies matching our search
criteria published up until the end of 2006. The
general form of the search for Medline is given
below. The terms ‘‘or’’ and ‘‘and’’ indicate the
standard Boolean operators; $ is an Ovid trunca-
tion symbol. Lower case terms indicate free-text
searches applied to all text fields (title, abstract,
keywords, etc). Capitalised words or phrases
(eg, Osteoarthritis) indicate MeSH (Medical
Subject Heading) terms, which were expanded to
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include index subheadings (including all available subcategories
of disease). The Medline search was adapted for Embase (in
which some MeSH terms differ from Medline) and for the SCI.
The search was designed to be as broad as possible. We chose to
identify a larger number of studies with the initial search and
then exclude irrelevant studies manually, rather than risking
using an excessively specific (and exclusive) strategy. In
addition, gene–disease association studies are sometimes per-
formed alongside other types of analysis (particularly linkage
analysis), making a search for related types of study a useful
means of identifying smaller association studies.
Search terms and structure
1. osteoarthriti$ or osteoarthrosis or osteoarthrotic or spon-
dylosis or osteophytosis
2. (degeneration or degenerative) adj6 (spine or spinal or disc
or discs or prolapse)
3. Osteoarthritis or Osteoarthritis (Hip) or Osteoarthritis
(Knee) or Spinal Osteophytosis
4. 1 or 2 or 3
5. gene or genes or genetic$ or genic or geno$ or chromosom$
or allel$ or homozygote or heterozygote or polymorph$ or
linkage$ or heritab$ or inherit$ or mutat$ or hered$
6. Heredity or Gene Frequency or Genotype or Gene Dosage or
Genetic Predisposition to Disease or Haplotypes or
Heterozygote or Homozygote or Inheritance Patterns or
Genes (Dominant) or Genes (Recessive) or Multifactorial
Inheritance or Quantitative Trait (Heritable) or Linkage
(Genetics) or Linkage Disequilibrium or Lod score or
Phenotype or Genetic Markers or Penetrance or Variation
(Genetics) or Genetic Heterogeneity or Mutation or
Polymorphism (Genetic) or Polymorphism (Restriction
Fragment Length) or Polymorphism (Single Nucleotide) or
Chromosomes or Genome or Genes or Alleles or Major
Histocompatibility Complex or Quantitative Trait Loci
7. 5 or 6
8. 4 and 7
9. Limit the above to human studies
The records for each article were checked individually using the
title and abstract, and those not dealing specifically with a
gene–OA or gene–SDD association were excluded. This initial
screen was carried out twice, once each by two members of the
review team, to serve as a double check. If it was not possible to
exclude articles at the screening stage (for example, if
insufficient details were given in the abstract to enable us to
judge content), paper or electronic copies were retrieved and re-
checked to determine whether or not any further articles should
be excluded (also with double-checking within the review
team).
Data extraction
We used a simple form to extract the following data from the
included studies:
c Study design.
c Type of disease and sites affected. We assigned joint
categories on the basis of the primary patient diagnosis of
OA (ie, hip, knee or hand) or SDD.
c Method of diagnosis (eg, radiographic).
c Total sample size and number of cases and controls. A
‘‘small’’ sample size was judged to be ,150 patients in total
(eg, less than 75 cases and 75 controls combined).7
c Proportion of cases male/female.
c Origin of case/control populations and recruitment setting
(eg, hospital, with geographic region).
c Gene(s) analysed, with type(s) and number(s) of poly-
morphism(s) (eg, vitamin D receptor, RFLP).
c Number of alleles per polymorphism (per gene).
c Details of associations and non-significant associations
reported.
c Whether or not we judged that a correction for multiple
testing may be appropriate, and if so whether or not one had
been applied.
c Whether or not any subgroup analyses were used and in
what context.
c Missing details: ethnicity, gender, age and details of the
recruitment process (eg, origin of the control population not
given).
Data extraction was carried out in duplicate by two
reviewers. Studies were categorised on the basis of sample size
following a recent meta-analysis of gene–disease association
studies,7 which found that discrepancies between the results of
first and subsequent studies of a particular association were
more common when the total sample size of the first study was
,150 (‘‘small’’) than when it was >150. We judged that
correction for multiple testing may be appropriate whenever
more than one genetic locus was tested for association, except
where the authors put forward an explicit argument as to why
correction was considered unnecessary (we made no judgement
concerning the validity of any such arguments). This criterion
was applied whether the loci under consideration were
polymorphic sites within separate genes (ie, a multiple gene
study) or discrete polymorphisms within the same gene.
To simplify the results, we grouped together studies that
focused on different polymorphic regions within the same gene.
This approach necessitates that we qualify our use of the term
‘‘replication’’ in the discussion below. In particular, we stress
that ‘‘replication’’ does not necessarily refer to a specific genetic
locus, only to the gene within which that locus occurs.
Therefore, where a significant association has been reported
for a particular gene–disease association in more than one study,
we have referred to this as replicated reporting of a significant
association, regardless of the specific gene variant.
FINDINGS
Our search identified 5748 articles in total, across all three
databases. The number of articles was reduced to 122 by the
initial screening process, which excluded irrelevant or unsuitable
studies on the basis of the title or abstract. Paper or electronic
copies of all 122 articles were retrieved and re-checked. A further
32 articles were excluded after it became apparent that they
were not association studies, leaving a total of 90 for data
extraction. Table 1 provides an overview of these studies,
grouped by joint category.
Gene–OA/SDD associations by joint category
Out of the 90 included studies, 68 reported finding one or more
significant gene–disease association(s). From these studies, 94
associations were reported from a total of 83 different genes
(table 1). Hip OA (HOA) and knee OA (KOA) studies were
most prevalent, but we found relatively few instances, either for
these or any other joint sites, in which the same gene–disease
association had been the focus of more than one study. There
were also very few examples of significant associations that had
been replicated in separate studies. For example, 31 studies
examined gene associations for HOA, analysing a total of 38
Review
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genes. Only 15 of these genes were represented by two or more
separate studies and there were only two cases in which a
significant association was replicated by another study.
Table 2 provides a more detailed summary of the number of
significant and non-significant associations for each gene
(grouped by joint category).
It is clear that the relatively low incidence of different studies
having focussed on the same gene–disease association (which is
apparent from table 1) is in part a consequence of the dilution of
study effort between different disease phenotypes. For example,
we found four studies that tested for an association with the
COL1A1 gene, but these were split between cases of HOA,
KOA, HOA and KOA combined, and SDD; only one of these
separate joint categories was represented by more than one
study. A similarly diffuse pattern of research effort is apparent
for many of the other genes shown on table 2, with a small
number of exceptions (such as the VDR gene, where four of the
six joint categories studied are represented by multiple studies).
Study designs, sample sizes and data analysis
The majority of studies had a sample size of >150 (table 3).7
There was no suggestion that the simple categorisation of
studies into groups with either , or >150 patients was
correlated with a tendency to report a significant association,
but caution needs to be exercised here as the number in the
‘‘small’’ category was low.
The majority of studies used some variation of a case–control
design to quantify associations, sometimes nesting within a
cohort study but more often sampling from a proxy control
population, whilst three studies used a family-based
design.14 47 93 Most studies analysed the association between a
genetic variant(s) and disease prevalence (presence or absence of
disease), whilst a smaller proportion focused on quantitative or
qualitative measures of disease severity (table 3). Less than a
third of all studies that reported a significant association and
tested across multiple loci applied any form of correction for a
raised type I error rate. Equally striking is the finding that,
regardless of sample size, over half of the studies failed to report
basic study details. Omissions were evident with regard to one
or more of: ethnicity, gender, age, and details of the recruitment
process. In many cases these omissions make it difficult to judge
whether or not reported associations could potentially be
confounded by population stratification, or whether controls
have been appropriately selected. Full results of analyses were
often not provided and many studies relied on subgroup
analyses. Taken together, these problems may create a
substantial risk of publication bias.
DISCUSSION
Our results show that there has been much research into gene–
OA and gene–SDD associations over the last decade. The 90
studies included in this review reported a total of 94 associations
from 83 different genes. Reasonably good evidence is emerging
in support of a role for certain genes. We found a number of
significant associations that have been replicated within a joint
category by two or more independent studies: AGC1,
hand;14 15 17 ASPN, hip and knee;19–22 COL9A2, spine;41 44
COL9A3, spine;39 45 COL11A2, spine;16 39 ESR1, knee;48 49 FZRB,
hip;9 54 55 HFE, hand;57 58 IL1A, knee;67 68 IL1RN, knee;67 68 PTGS2,
knee;10 11 and VDR, knee and spine.50 52 89–94 We also found
several studies where significant associations (FRZB and IL1
gene cluster) were replicated in separate populations.9 53 68
However, in the majority of cases where a significant associa-
tion had been reported and the same gene–disease association
had been tested in another study, the association had not been
found again. Therefore, it is unclear to what extent these
isolated significant associations are in fact ‘‘false positives’’. This
problem is confounded by the fact that separate studies of the
same gene and the same disease phenotype sometimes focus on
different polymorphisms within the gene. In such cases, the
association may not have been replicated with respect to the
same genetic unit (ie, the genetic locus).
Thus, despite the obvious progress that has been made,
isolated gene–OA/SDD studies are very common (103 out of a
total of 157 by joint category; table 1) and relatively few genes
have been the subject of more than two or three studies within
any particular joint category (table 2). The complex phenotype
of the disease undoubtedly makes it difficult to prioritise
research areas and may encourage a somewhat uncoordinated
and diffuse approach when the field is viewed as a whole.
Indeed, the degree to which different types of OA and SDD
genuinely represent discrete forms of disease, with distinct
aetiologies, is far from clear. The sheer number of potential
gene–OA associations inevitably adds to this problem.
However, we suggest that substantial progress could be
achieved from focusing on those candidate genes where
evidence seems to be growing (eg, VDR). If we continue instead
to cast the ‘‘net’’ ever wider in an attempt to detect new
associations, unreplicated and untested results will simply
continue to accumulate without adding much to our under-
standing. A more convincing approach may be to carry out
smaller numbers of large, high quality, genome-wide association
studies (eg, Spector et al).77
A further problem is that relatively simple and avoidable
methodological and reporting problems frequently undermine
Table 1 Overview of included studies (n = 90), grouped by joint category, showing genes analysed,
numbers of significant associations, and replication across studies
Total no. of:
Joints affected
Hip Knee Hip/knee Hand Spine Multiple Any
Studies 31 35 5 17 23 8 4
Significant associations 19 30 5 9 22 6 3
Genes analysed 38 53 16 13 19 14 4
Genes reported to be significantly
associated
16 23 5 6 15 5 3
Genes analysed by >2 studies* 15 26 0 3 8 2 0
Significant associations replicated{ 2 6 0 2 4 1 0
’’Multiple’’ indicates patients with OA in two or more major joint groups (typically some form of hand OA plus OA in one other
major joint). The ‘‘Hip/knee’’ and ‘‘Any’’ categories indicate that hip and knee OA patients, or patients with OA in any joint,
respectively, were pooled by the authors of the respective study.
*Repetition of a specific gene-joint association analysis by two or more studies (see text for details).
{Instances of replicated reporting of a significant gene–OA association by two or more studies (see text for details).
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Table 2 Summary of gene–osteoarthritis (OA)/spinal degenerative disease (SDD) association studies
Gene*
Joints affected{
ReferencesHip Knee Hip/knee Hand Spine Multiple Any
ACE 0/1 Hong et al8
ACVR1 0/1 Loughlin et al9
ADAM12 1/2 Valdes et al 10 11
ADAMTS3 1/1 Kawahara et al12
AEBP1 0/1 Valdes et al10
AGC1 1/1 0/2 3/3 1/2 Kawaguchi et al,13 Kirk et al,14 Horton et al,15
Noponen-Hietala et al16 and Kamarainen et al17
AR 1/1 Fytili et al18
ASPN 2/3 3/5 1/1 0/1 Kizawa et al,19 Mustafa et al,20 Jiang et al,21
Kaliakatsos et al22 and Rodriguez-Lopez et al23
ATF2 0/1 Loughlin et al9
BGN 0/1 Valdes et al10
BMP2 1/2 Valdes et al10 11
BMP5 1/1 Southam et al24
BMPR1A 0/1 Valdes et al10
CALM1 1/2 Mototani et al,25 and Loughlin et al26
CD36 1/2 Valdes et al10 11
CD55 0/1 Valdes et al10
CILP 1/2 1/1 Valdes et al10 11 and Seki et al 27
CLEC3B 1/2 Valdes et al10 11
COL1A1 1/3 0/1 0/1 1/1 Aerssens et al,28 Loughlin et al,29 Lain et al30 and
Pluijm et al31
COL2A1 0/4 1/3 0/1 0/1 0/1 1/3 Aerssens et al,28 Granchi et al,32 Ikeda et al,33
Jakkula et al,34 Meulenbelt et al,35 Priestley et al,36
Vikkula et al,37 Uitterlinden et al38 and Solovieva et al 39
COL9A1 1/3 0/2 0/1 0/1 Ikeda et al,33 Jakkula et al,34 Alizadeh et al40 and
Jim et al41
COL9A2 0/2 0/2 0/1 2/4 Ikeda et al,33 Jakkula et al,34 Jim et al,41 Kales et al,42
Seki et al43 and Annunen et al44
COL9A3 0/2 1/2 1/1 2/4 Ikeda et al,33 Jakkula et al,34 Solovieva et al,39 45
Jim et al,41 and Kales et al42
COL10A1 0/2 0/2 0/1 Ikeda et al33 and Jakkula et al34
COL11A1 0/2 0/2 0/1 Ikeda et al33 and Jakkula et al34
COL11A2 0/2 0/2 0/1 2/2 Noponen-Hietala et al,16 Ikeda et al,33 Jakkula et al34
and Solovieva et al39
COMP 0/1 0/2 Valdes et al10 and Mabuchi et al46
CTSL 0/1 Valdes et al10
ENPP1 1/1 Suk et al47
ESR1 0/1 2/6 0/1 0/2 1/1 Valdes et al,10 11 Fytili et al,18 Loughlin et al,29
Bergink et al,48 Jin et al,49 Kawagichi et al,50
Ushiyama et al51 and Koshizuka et al52
ESR2 1/1 Fytili et al18
FAP 0/1 Loughlin et al9
FRZB 3/5 2/2 Loughlin et al,9 Min et al,53 Lane et al54 and Lories
et al 55
HAPLN1 0/1 0/1 Meulenbelt et al56
HFE 0/1 0/1 2/2{ Ross et al,57 Carroll58 and Loughlin et al59
HLA-A 0/1 Wakitani et al60
HLA-B 0/1 Wakitani et al60
HLA-C 1/1 Wakitani et al60
HLA-DQA1 0/1 Wakitani et al60
HLA-DQB1 0/1 Wakitani et al60
HLA-DRB1 1/1 0/1 0/1 1/1 Wakitani et al,60 Moos et al61 and Rovetta et al62
HLA-DRB3 0/1 Wakitani et al60
IBSP 0/1 Valdes et al10
IGF1 1/1 1/1 1/1 1/1 0/1 1/1 Meulenbelt et al63
IGF2 1/1 Zhai et al64
IGFBP7 0/1 Kawahara et al12
IL1A 0/1 2/2 0/1 1/1 Solovieva et al,65 Stern et al,66 Loughlin et al67 and
Smith et al68
IL1B 1/2 1/2 1/1 1/1 1/2 Koshizuka et al,52 Solovieva et al,65 Stern et al,66
Loughlin et al,67 Smith et al,68 Moos et al69 and
Meulenbelt et al70
IL1R1 0/1 Smith et al68
Continued
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Table 2 Continued
Gene*
Joints affected{
ReferencesHip Knee Hip/knee Hand Spine Multiple Any
IL1RN 1/2 2/2 1/1 0/1 1/1 Solovieva et al,65 Stern et al,66 Loughlin et al,67
Smith et al,68 Moos et al69 and Meulenbelt et al70
IL4R 1/1 Forster et al71
IL6 1/1 0/1 Moos et al69 and Pola et al72
IL8 0/1 Kawahara et al12
IL10 1/1 0/1 Riyazi et al73 and Fytili et al74
IL17A 0/1 Southam et al75
IL17F 0/1 Southam et al75
ITGA4 0/1 Loughlin et al9
ITGA5 0/1 Loughlin et al9
ITGA6 1/1 Loughlin et al9
KL 1/1 Ogata et al76
LRCH1 1/1 Spector et al77
LRP5 1/1 Smith et al78
MATN1 1/2 0/2 0/1 Meulenbelt et al,56 Strusberg et al79 and Loughlin et al80
MATN3 0/1 0/1 0/1 1/1 Min et al81
Mit. seq1 0/1 Chang et al82
MMP3 0/1 1/2 Valdes et al,10 Noponen-Hietala et al16 and
Takahashi et al83
MXRA5 0/1 Valdes et al10
NCOR2 1/2 Valdes et al10 11
OGN 0/1 Valdes et al10
PAPSS2 0/1 Ikeda et al84
PPARG 0/1 Cheng et al85
PTGS2 2/2 Valdes et al10 11
PTH 0/1 Koshizuka et al52
SERPINA1 0/1 Sakkas et al86
SERPINA3 1/2 1/1 Valdes et al10 11 and Sakkas et al86
SLC26A2 1/1 Ikeda et al84
SOD3 0/1 Valdes et al10
TGFB1 1/1 Yamada et al87
TIMP1 0/1 Valdes et al10
TNF 0/1 Moos et al69
TNFAIP6 1/1 0/2 Loughlin et al9 and Valdes et al10 11
TNFRSF11B 0/2 Valdes et al10 11
VDR 0/4 2/7 0/1 1/4 5/8 0/1 Valdes et al,10 11 Noponen-Hietala et al,16 Aerssens
et al,28 Loughlin et al,29 Granchi et al,32 Kawaguchi
et al,50 Koshizuka et al,52 Huang et al,88 Jones et al,89
Jordan et al,90 Keen et al,91 Uitterlinden et al,92
Videman et al,93 Cheung et al,94 Solovieva et al95 and
Baldwin et al96
The total numbers of significant associations for each joint group are expressed in relation to the total number of studies per gene/joint combination (eg, AGC1, Spine = 1/2: one
significant association reported from two separate studies).
*See table 1.
{Symbols as approved by the Human Genome organisation (HUGO; see http://ash.gene.ucl.ac.uk/nomenclature/). Approved gene names are as follows: ACE, angiotensin I
converting enzyme; ACVR1, activin A receptor, type I; ADAM12, ADAM metallopeptidase domain 12; ADAMTS3, ADAM metallopeptidase with thrombospondin type 1 motif, 3;
AEBP1, AE binding protein 1; AGC1, aggrecan 1; AR, androgen receptor; ASPN, asporin; ATF2, activating transcription factor 2; BGN, biglycan; BMP2, bone morphogenetic protein
2; BMP5, bone morphogenetic protein 5; BMPR1A, bone morphogenetic protein receptor, type IA; CALM1, calmodulin 1; CD36, CD36 molecule; CD55, CD55 molecule; CILP,
cartilage intermediate layer protein, nucleotide pyrophosphohydrolase; CLEC3B, C-type lectin domain family 3, member B; COL1A1, collagen, type I, alpha 1; COL2A1, collagen, type
II, alpha 1; COL9A1, collagen, type IX, alpha 1; COL9A2, collagen, type IX, alpha 2; COL9A3, collagen, type IX, alpha 3; COL10A1, collagen, type X, alpha 1; COL11A1, collagen, type
XI, alpha 1; COL11A2, collagen, type XI, alpha 2; COMP, cartilage oligomeric matrix protein; CTSL, cathepsin L; ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase 1; ESR1,
oestrogen receptor 1; ESR2, oestrogen receptor 2; FAP, fibroblast activation protein, alpha; FRZB, frizzled-related protein; HAPLN1, hyaluronan and proteoglycan link protein 1; HFE,
haemochromatosis; HLA-A, major histocompatability complex (MHC), class I, A; HLA-B, MHC, class I, B; HLA-C, MHC, class I, C; HLA-DQA1, MHC, class II, DQ alpha 1; HLA-DQB1,
MHC, class II, DQ beta 1; HLA-DRB1, MHC, class II, DR beta 1; HLA-DRB3, MHC, class II, DR beta 3; IBSP, integrin-binding sialoprotein; IGF1, insulin-like growth factor 1; IGF2,
insulin-like growth factor 2; IGFBP7, insulin-like growth factor binding protein 7; IL1A, interleukin 1, alpha; IL1B, interleukin 1, beta; IL1R1, interleukin 1 receptor, type I; IL1RN,
interleukin 1 receptor antagonist; IL4R, interleukin 4 receptor; IL6, interleukin 6; IL8, interleukin 8; IL10, interleukin 10; IL17A, interleukin 17A; IL17F, interleukin 17F; ITGA4, integrin,
alpha 4; ITGA5, integrin, alpha 5; ITGA6, integrin, alpha 6; KL, klotho; LRCH1, leucine-rich repeats and calponin homology (CH) domain-containing 1; LRP5, low density lipoprotein
receptor-related protein 5; MATN1, matrilin 1, cartilage matrix protein; MATN3, matrilin 3; MMP3, matrix metallopeptidase 3; MXRA5, matrix-remodelling associated 5;
NCOR2,nuclear receptor co-repressor 2; OGN, osteoglycin; PAPSS2, 39-phosphoadenosine 59-phosphosulfate synthase 2; PPARG, peroxisome proliferator-activated receptor
gamma; PTGS2, prostaglandin-endoperoxide synthase 2; PTH, parathyroid hormone; SERPINA1, serpin peptidase inhibitor, clade A, member 1; SERPINA3, serpin peptidase inhibitor,
clade A, member 3; SLC26A2, solute carrier family 26, member 2; SOD3, superoxide dismutase 3, extracellular; TGFB1, transforming growth factor, beta 1; TIMP1, TIMP
metallopeptidase inhibitor 1; TNF, tumour necrosis factor; TNFAIP6, tumour necrosis factor, alpha-induced protein 6; TNFRSF11B, tumour necrosis factor receptor superfamily,
member 11b; VDR, vitamin D receptor. {Association also reported for the ankle for this gene,97 although not replicated in Carroll.58
1 mtDNA deletion of 4977 base pairs.
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the degree of confidence that can be placed in individual gene–
OA/SDD association studies. First, we found that many studies
provided insufficient detail to enable the reader to assess
whether or not bias could have confounded the analysis (eg,
unreported age-biases).6 It should be standard practice to report
full case and control population details. Second, many studies
tested for associations across multiple loci, but did not apply
any form of correction for type I statistical errors. The problem
of spurious association may therefore be inflated by the use of
inappropriate (permissive) significance levels, presenting a
serious challenge to the development of clear, well-supported
conclusions. Third, in many cases the main associations
reported in a study were derived from some form of subgroup
analysis. Whilst this approach may be perfectly valid in the right
context, it may be misleading not to include strong caveats. For
example, significant associations derived from post hoc sub-
group analyses may be emphasised in the abstract of a study
over and above the results of the primary analysis of the study,
if the latter are non-significant. The omission of appropriate
caveats from the abstract of a study can only encourage biased
reporting and interpretation. Fourth, many studies failed to
report results in full, adding to the familiar concern regarding
the degree to which non-significant results are being under-
reported.
Huizinga et al have provided recommendations for the
conduct of gene–OA association studies; Little et al also recently
gave a detailed overview of a wide-range of issues that arise in
the appraisal of gene–disease association studies.98–100 These
studies offer detailed recommendations to aid authors in the
preparation of manuscripts and to help readers assess study
design and quality. It is undoubtedly too soon to expect these
recommendations to have been applied fully in all but the most
recent cases (and many studies included here predate these
overviews), but our results illustrate why they must be applied
in future studies. Adequate replication and attention to study
design, methodology and reporting is demonstrably lacking, as
is a clear delineation between hypothesis testing vs hypothesis
generation. A clearer approach to disease phenotype in the OA/
SDD field is also vital. Taken together, these problems present a
major obstacle to the systematic review and/or meta-analysis of
effect sizes for particular associations. A key challenge for future
studies will be to actively minimise the potential for publication
bias. For example, the value of published association analyses will
be greatly undermined if unpublished studies and datasets are
allowed to accumulate beyond the range of the systematic
reviewer’s ‘‘radar’’. The Human Genome Epidemiology Network
(HuGENet) has been at the leading edge of calls for registries and
investigator networks aimed at overcoming this problem.101
In summary, our primary concern in this review has been to
provide an overview of general progress and to highlight areas
where it appears that improvements are possible. Whilst it is
clear that real progress has been made in the genetic
epidemiology of OA and SDD, future association analyses must
deal with a range of important problems. Greater focus and
coordination between researchers is vital,101 particularly in light
of advances in gene-scanning technology, which mean that the
potential now exists for the number of reported significant
associations to grow at an accelerating rate. As our under-
standing of the genetic architecture of OA grows, hypothesis
testing should become a more realistic and achievable goal.
Additionally, basic epidemiological principles must be applied
with greater vigour and a clearer standard of reporting
maintained, in keeping with the recommendations of
HuGENet. We also hope that funding bodies will begin to
prioritise research that follows these well-tested principles.
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